- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about GILD
Recent news which mentions GILD
2 Top Dividend Stocks to Buy Hand Over Fist
March 17, 2024
From Motley Fool
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
March 15, 2024
From Benzinga
From Benzinga
3 Dividend Stocks to Buy Hand Over Fist in March
March 10, 2024
From Motley Fool
The AI Race Gets Litigious
March 09, 2024
From Motley Fool
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
From Benzinga
From Benzinga
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy
March 06, 2024
From Benzinga
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
March 06, 2024
From Benzinga
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
March 04, 2024
From InvestorPlace
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges
March 04, 2024
From Benzinga
3 Dividend Stocks That Are No-Brainer Buys Right Now
February 24, 2024
From Motley Fool
History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20%
February 24, 2024
Tickers
GILD
From Motley Fool
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today
February 23, 2024
From Benzinga
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
From InvestorPlace
Stock Alert: 3 Market Giants on the Brink of Monumental Rallies
February 20, 2024
From InvestorPlace
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
February 19, 2024
From InvestorPlace
Why Is Gilead Sciences Stock Trading Lower Today?
February 16, 2024
From Benzinga
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
From InvestorPlace
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
February 14, 2024
From Benzinga
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
February 13, 2024
From Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
February 12, 2024
From Benzinga
From Benzinga
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
February 12, 2024
From Benzinga
Top 5 Health Care Stocks That Are Preparing To Pump In February
February 09, 2024
From Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
From InvestorPlace
S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?
February 07, 2024
From Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
February 07, 2024
From Benzinga
2 Beaten-Down Dividend Stocks to Buy Hand Over Fist
February 07, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.